Literature DB >> 1684387

The dynamics of CD4+ T-lymphocyte decline in HIV-infected individuals: a Markov modeling approach.

I M Longini1, W S Clark, L I Gardner, J F Brundage.   

Abstract

We modeled the decline of CD4+ T-lymphocytes (T4 cells) in HIV-infected individuals with a continuous-time Markov process. The model partitions the HIV infection period into six progressive T4-cell count intervals (states), followed by a seventh state: a definitive HIV-infection end point, i.e., AIDS diagnosis or Walter Reed stage 6 (opportunistic infections). The Markov model was used to estimate the state-specific progression rates from data as functions of important progression cofactors. We applied the model to data on 1,796 HIV-positive individuals in the U.S. Army. The estimated mean waiting time from seroconversion to when the T4-cell count persistently drops below 500/mm3, but is greater than 349/mm3, is 4.1 years, and the waiting time to a T4-cell count of less than 200/mm3 is estimated at 8.0 years. The estimated rate of T4-cell decline was higher for HIV-infected individuals with initially high numbers of T4 cells, but the estimated rate of decline remains relatively uniform when the T4-cell count dropped persistently below 500/mm3. The opportunistic infection incubation period, i.e., the time from seroconversion to opportunistic infection diagnosis, is estimated at 9.6 years. Age is found to be an important cofactor. The estimated mean opportunistic infection incubation periods are 11.1, 10.0, and 8.9 years for the youngest (less than or equal to 25 years old), the middle (26-30 years old), and the oldest (greater than 30 years old) age groups, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1684387

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr (1988)        ISSN: 0894-9255


  17 in total

1.  Risk-based HIV testing in South Carolina health care settings failed to identify the majority of infected individuals.

Authors:  Wayne A Duffus; Kristina Weis; Lynda Kettinger; Terri Stephens; Helmut Albrecht; James J Gibson
Journal:  AIDS Patient Care STDS       Date:  2009-05       Impact factor: 5.078

2.  How should access to antiretroviral treatment be measured?

Authors:  Leigh F Johnson; Andrew Boulle
Journal:  Bull World Health Organ       Date:  2011-02-01       Impact factor: 9.408

3.  Modelling the cost effectiveness of lamivudine/zidovudine combination therapy in HIV infection.

Authors:  J V Chancellor; A M Hill; C A Sabin; K N Simpson; M Youle
Journal:  Pharmacoeconomics       Date:  1997-07       Impact factor: 4.981

4.  Monitoring the incidence of HIV infection in the United States.

Authors:  Lisa M Lee; Matthew T McKenna
Journal:  Public Health Rep       Date:  2007       Impact factor: 2.792

Review 5.  HIV and aging: implications for patient management.

Authors:  Kelly A Gebo
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

6.  Estimation of HIV incidence in the United States.

Authors:  H Irene Hall; Ruiguang Song; Philip Rhodes; Joseph Prejean; Qian An; Lisa M Lee; John Karon; Ron Brookmeyer; Edward H Kaplan; Matthew T McKenna; Robert S Janssen
Journal:  JAMA       Date:  2008-08-06       Impact factor: 56.272

7.  Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions.

Authors:  Rita B Effros; Courtney V Fletcher; Kelly Gebo; Jeffrey B Halter; William R Hazzard; Frances McFarland Horne; Robin E Huebner; Edward N Janoff; Amy C Justice; Daniel Kuritzkes; Susan G Nayfield; Susan F Plaeger; Kenneth E Schmader; John R Ashworth; Christine Campanelli; Charles P Clayton; Beth Rada; Nancy F Woolard; Kevin P High
Journal:  Clin Infect Dis       Date:  2008-08-15       Impact factor: 9.079

8.  Early HIV treatment in the United States prevented nearly 13,500 infections per year during 1996-2009.

Authors:  Dana P Goldman; Timothy Juday; Daniel Seekins; Mark T Linthicum; John A Romley
Journal:  Health Aff (Millwood)       Date:  2014-03       Impact factor: 6.301

9.  A Bayesian hierarchical model with novel prior specifications for estimating HIV testing rates.

Authors:  Qian An; Jian Kang; Ruiguang Song; H Irene Hall
Journal:  Stat Med       Date:  2015-11-15       Impact factor: 2.373

10.  Cost-effectiveness analysis of Option B+ for HIV prevention and treatment of mothers and children in Malawi.

Authors:  Olufunke Fasawe; Carlos Avila; Nathan Shaffer; Erik Schouten; Frank Chimbwandira; David Hoos; Olive Nakakeeto; Paul De Lay
Journal:  PLoS One       Date:  2013-03-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.